ArticleMedicine2025
Fu's subcutaneous needling for chronic gastritis with observations on serum gastric function indices: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleFu's subcutaneous needling (FSN) is an innovative acupuncture therapy derived from traditional techniques. It employs disposable floating needles and auxiliary needle guides to conduct a broad, swaying motion. The therapy aims to enhance blood perfusion and oxygen supply to local muscles, activate the body's self-healing mechanisms, and ultimately promote drug-free recovery. This case study examines FSN's application in treating chronic gastritis (CG) and and its effects on serum gastric function indices. PATIENT CONCERNS: A 44-year-old female patient presented with complaints of epigastric discomfort, nonspecific pain or a burning sensation, along with occasional belching, anorexia, nausea, and vomiting. Additionally, the patient reported poor sleep quality and the presence of formless stools. DIAGNOSES: The patient was diagnosed with CG by gastroscopy.
interventionsFSN was administered 3 times/wk. No adverse or unanticipated events were observed during the treatment period. The entire treatment course spanned a duration of 4 weeks. OUTCOMES: Following the treatment, the patient reported the absence of significant discomfort in her epigastrium, and noted the resolution of both vague pain and burning sensation. Additionally, she experienced an increase in appetite, regular bowel movements, and improved sleep quality. LESSONS: FSN has been demonstrated to significantly alleviate epigastric discomfort associated with CG and to have a positive impact on appetite, sleep quality, and bowel movements. Moreover, FSN demonstrates a significant and sustained improvement in serum gastric function indices, with no observed relapse. However, due to the limitations inherent in a single clinical observation case, further randomized controlled clinical trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.